Literature DB >> 15033177

Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.

Craig D C Bailey1, Robert M Graham, Nisha Nanda, Peter J A Davies, Gail V W Johnson.   

Abstract

Tissue transglutaminase (tTG) is a multifunctional enzyme that catalyzes peptide cross-linking and polyamination reactions, and also is a signal-transducing GTPase. tTG protein content and enzymatic activity are upregulated in the brain in Huntington's disease and in other neurological diseases and conditions. Since mouse models are currently being used to study the role of tTG in Huntington's disease and other neurodegenerative diseases, it is critical that the level of its expression in the mouse forebrain be determined. In contrast to human forebrain where tTG is abundant, tTG can only be detected in mouse forebrain by immunoblotting a GTP-binding-enriched protein fraction. tTG mRNA content and transamidating activity are approximately 70% lower in mouse than in human forebrain. However, tTG contributes to the majority of transglutaminase activity within mouse forebrain. Thus, although tTG is expressed at lower levels in mouse compared with human forebrain, it likely plays important roles in neuronal function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15033177     DOI: 10.1016/j.mcn.2003.11.016

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  9 in total

1.  Transglutaminase 2 protects against ischemic stroke.

Authors:  A J Filiano; J Tucholski; P J Dolan; G Colak; G V W Johnson
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

2.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.

Authors:  Boris F Krasnikov; Soo-Youl Kim; Stephen J McConoughey; Hoon Ryu; Hui Xu; Irina Stavrovskaya; Siiri E Iismaa; Bryony M Mearns; Rajiv R Ratan; John P Blass; Gary E Gibson; Arthur J L Cooper
Journal:  Biochemistry       Date:  2005-05-31       Impact factor: 3.162

3.  Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia.

Authors:  Gozde Colak; Gail V W Johnson
Journal:  Neurobiol Dis       Date:  2011-12-14       Impact factor: 5.996

4.  Beta-actin is a target for transglutaminase activity at synaptic endings in chicken telencephalic cell cultures.

Authors:  Lars Dolge; Karin Aufenvenne; Heiko Traupe; Werner Baumgartner
Journal:  J Mol Neurosci       Date:  2011-07-26       Impact factor: 3.444

5.  The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.

Authors:  Qingmin Ruan; Janusz Tucholski; Soner Gundemir; Gail V W Johnson Voll
Journal:  Int J Clin Exp Med       Date:  2008-06-30

6.  Anti transglutaminase antibodies cause ataxia in mice.

Authors:  Sabrina Boscolo; Andrea Lorenzon; Daniele Sblattero; Fiorella Florian; Marco Stebel; Roberto Marzari; Tarcisio Not; Daniel Aeschlimann; Alessandro Ventura; Marios Hadjivassiliou; Enrico Tongiorgi
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

7.  Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.

Authors:  Anthony J Filiano; Craig D C Bailey; Janusz Tucholski; Soner Gundemir; Gail V W Johnson
Journal:  FASEB J       Date:  2008-03-28       Impact factor: 5.191

8.  Transglutaminase 6: a protein associated with central nervous system development and motor function.

Authors:  Helen Thomas; Konrad Beck; Magdalena Adamczyk; Pascale Aeschlimann; Martin Langley; Radu C Oita; Lars Thiebach; Martin Hils; Daniel Aeschlimann
Journal:  Amino Acids       Date:  2011-10-08       Impact factor: 3.520

9.  Intracellular localization and conformational state of transglutaminase 2: implications for cell death.

Authors:  Soner Gundemir; Gail V W Johnson
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.